Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaRe: Rhenium-188-HEDP vs Radium-223 in mCRPC
NCT03458559Phase 3Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Radiopharmaceutical, RT (Radiation Therapy)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rhenium-188-HEDP in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall Survival at 18 months. Status: unknown.
02
Drugs
Rhenium-188-HEDP
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03458559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458559.